Kala Pharmaceuticals Announces $22.5 Million Series B Financing

por Ysios Capital

Kala Pharmaceuticals, Inc., a leading developer of innovative ophthalmic products based on the company’s proprietary Mucus Penetrating Particle (MPP) platform technology, today announced it has comp...

Leer más
Subscribirse al Directorio
Escribir un Artículo

Destacadas

Axon moves into Cloud Technology

by Axon Partners Group

cloud technology

Mediterrania Capital Partners completa e...

by Mediterrania Capital Partners

A lo largo de la inversión de MC III, TGCC no solo ha logrado éxitos...

Diapositiva de Fotos